Outsourcing Solid Dose Manufacturing Trends In 2014
In 2014, the contract manufacturing market for solid dosage forms is anticipated to be $19.6B, representing 58% of the total CMO market value of $33.7B. While the market value percentage for solid dose has been drifting downward — likely related to the shift towards biologics, which are more expensive to develop and manufacture — the propensity to outsource oral solid dosage forms continues to grow modestly.
WHITE PAPERS & CASE STUDIES
Fluid Bed System Triples Batch Sizes for Laboratorios Normon while Reducing Costs
With the aim of reducing costs, Normon planned to significantly increase its batch sizes for certain products. The manufacturer needed to pay close attention to the high quality and safety standards and economic aspects, as well as flexible production sizes and times.
Efficiencies In Powder Dispersion For Manufacturers
This white paper explores five tips for dispersing powders into liquid more efficiently.
Medication Errors -- A Threat To Patient Safety: Mitigating Errors With Tablet Appearance
Medical prescription drug errors by doctors, pharmacists and patients account for 1.5 million incidences of sickness, injuries or deaths in the U.S. each year. By Jay Anbil and Steve Yoder
Film Coating For Pediatric Oral Solid Dosage Forms
From a recent survey conducted within the pharmaceutical industry, by Colorcon, it was confirmed that oral solid dosage forms are a preferred choice for formulation of pediatric medicines.
How To Achieve A Dramatic Yield Increase Through The Use Of Anti-Segregation Technologies
A unique solution improves yields from less than 75% to over 98%.
Accelerating Lipid-Based Drug Formulation Through Application Of An Expert System
Formulation scientists have become pivotal to pharmaceutical development, in that they are often faced with the daunting challenge of not only identifying the most suitable drug delivery platform among a myriad of options, but also developing and validating robust systems that address the challenges posed by increasingly complex drug candidates, in ever shortening time frames. By Eduardo Jule, Ph.D., Senior Manager, Formulation and Pharmaceutical Development